← Cancer Research Communications
Papers in Cancer Research Communications
Page 7 · newest first
- Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular VesiclesCancer Research Communications · 2025
- The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer TumorigenesisCancer Research Communications · 2025
- Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer PatientsCancer Research Communications · 2025
- In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell CarcinomaCancer Research Communications · 2025
- Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with RadiotherapyCancer Research Communications · 2025
- Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian CancerCancer Research Communications · 2025
- Assessing MC1R Variants in Lentigo Maligna Melanoma within the Utah PopulationCancer Research Communications · 2025
- Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung CancerCancer Research Communications · 2025
- Adiposity Status Close to Diagnosis and Its Association with Prostate Cancer Survival in the UK BiobankCancer Research Communications · 2025
- A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 YearsCancer Research Communications · 2025
- Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid TumorsCancer Research Communications · 2025
- Protein-Level Analysis of Differential Response to Chemotherapy in Triple-Negative Breast Cancer Identifies CYP1B1 as a Biomarker for Chemotherapy ResistanceCancer Research Communications · 2025
- Genetic Ancestry, Intrinsic Tumor Subtypes, and Breast Cancer Survival in Latin American WomenCancer Research Communications · 2025
- Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World DataCancer Research Communications · 2025
- Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma CellsCancer Research Communications · 2025
- Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing LossCancer Research Communications · 2025
- High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic TargetCancer Research Communications · 2025
- An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without LymphocytopeniaCancer Research Communications · 2025
- A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2Cancer Research Communications · 2025
- A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial SarcomaCancer Research Communications · 2025
- Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate CancerCancer Research Communications · 2025
- Dual Role of NRF2 in Pancreatic Precursor LesionsCancer Research Communications · 2025
- First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid TumorsCancer Research Communications · 2025
- NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in GlioblastomaCancer Research Communications · 2025
- Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCancer Research Communications · 2025
- Targeting the Glucose–Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer GrowthCancer Research Communications · 2025
- Repurposing Amiodarone for Bladder Cancer TreatmentCancer Research Communications · 2025
- Modeled Benefit of Individual Cancer Signal Origin Prediction for Multi-Cancer Early DetectionCancer Research Communications · 2025
- PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural MesotheliomaCancer Research Communications · 2025
- Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Patients from Puerto Rico and FloridaCancer Research Communications · 2025
- APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung CancerCancer Research Communications · 2025
- Impact of Subcutaneous Versus Orthotopic Implantations on Patient-Derived Xenograft Transcriptomic ProfilesCancer Research Communications · 2025
- P4HA1 Mediates Hypoxia-Induced Invasion in Human Pancreatic Cancer OrganoidsCancer Research Communications · 2025
- Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN StudyCancer Research Communications · 2025
- Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312Cancer Research Communications · 2025
- Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1 , BRCA2 , ATM , CHEK2 , and PALB2Cancer Research Communications · 2025
- Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous CarcinomaCancer Research Communications · 2025
- Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaCancer Research Communications · 2025
- Mucosal Microbiome Markers of Complete Pathologic Response to Neoadjuvant Therapy in Rectal CarcinomaCancer Research Communications · 2025
- Inferring Drug–Gene Relationships in Cancer Using Literature-Augmented Large Language ModelsCancer Research Communications · 2025
- Social–Environmental Burden Is Associated with Increased Colorectal Cancer Mortality in Metropolitan DetroitCancer Research Communications · 2025
- Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsCancer Research Communications · 2025
- Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic SimilarityCancer Research Communications · 2025
- The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N TrialsCancer Research Communications · 2025
- PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid LeukemiaCancer Research Communications · 2025
- Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function MutationCancer Research Communications · 2025
- A Blood-Based Assay for Detection of Patients with Advanced AdenomasCancer Research Communications · 2025
- Osteosarcoma Exosome Priming of Primary Human Lung Fibroblasts Induces an Immune Modulatory and Protumorigenic PhenotypeCancer Research Communications · 2025
- Patients with Cervical Cancer with and without HIV Infection Have Unique T-cell Activation Profiles despite Similar Survival Outcomes after ChemoradiationCancer Research Communications · 2025
- Age and Sex Differences in the Prevalence of Specific Comorbidities among Patients with Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma at DiagnosisCancer Research Communications · 2025